Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24^th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET.

A live audio webcast of the presentation will be available on the Investors section of the Company’s website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products include ONPATTRO^® (patisiran), AMVUTTRA^® (vutrisiran), GIVLAARI^® (givosiran), and OXLUMO^® (lumasiran), which are being developed and commercialized by Alnylam, and Leqvio^® (inclisiran) and Qfitlia^™ (fitusiran), which are being developed and commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P⁵x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250401950208/en/

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

FAQ

When is Alnylam (ALNY) presenting at the Needham Healthcare Conference 2025?

Alnylam (ALNY) will present on Tuesday, April 8, 2025, at 11:45 am ET at the Needham 24th Annual Virtual Healthcare Conference.

How can investors watch Alnylam's (ALNY) Needham Conference presentation?

Investors can watch the live audio webcast through the Investors section at www.alnylam.com/events, with a replay available within 48 hours after the presentation.

What type of presentation will Alnylam (ALNY) give at the Needham Conference?

Alnylam's management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference.

How long will Alnylam's (ALNY) Needham Conference presentation be available for replay?

The presentation replay will be available on Alnylam's website within 48 hours after the event.